Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MT 3724

Drug Profile

MT 3724

Alternative Names: MT-3724

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Templates
  • Developer Banner MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Molecular Templates; University of Arizona; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Bacterial toxins; Drug conjugates; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Apoptosis stimulants; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma

Most Recent Events

  • 16 Jun 2021 Molecular Templates terminates a phase II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in USA (IV), due to sponsor's decision (NCT03488251)
  • 16 Jun 2021 Molecular Templates terminates phase II trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in USA due to sponsor's decision (IV) (NCT03645395)
  • 05 Apr 2021 Discontinued - Phase-I/II for Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in Georgia, Moldova, Canada, Ukraine, Belarus, Poland, Spain (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top